UNITED STATES                      SEC FILE NUMBER
                   SECURITIES AND EXCHANGE COMMISSION                0-27937
                         WASHINGTON, D.C. 20549                    CUSIP NUMBER

                               FORM 12b -25

                           NOTIFICATION OF LATE FILING

Check One:

     [ ]Form 10-K   [ ]Form 20-F   [ ]Form 11-K   [X]Form 10-QSB   [ ]Form N-SAR

     For Period Ended: June 30, 2005 
     [ ] Transition Report on Form 10-K 
     [ ] Transition Report on Form 20-F 
     [ ] Transition Report on Form 11-K 
     [ ] Transition Report on Form 10-Q 
     [ ] Transition Report on Form N-SAR 
     For the Transition Period Ended:
                                      --------------------------

If the notification relates to a portion of the filing check above, identify the
Item(s) to which the notification relates:

--------------------------------------------------------------------------------
PART I -- REGISTRANT INFORMATION
--------------------------------------------------------------------------------

         DRAGON PHARMACEUTICAL INC.
         -----------------------------------------------------------------------
         Full Name of Registrant


         -----------------------------------------------------------------------
         Former Name if Applicable


         1900-1055 West Hastings Street
         -----------------------------------------------------------------------
         Address of Principal Executive Office (Street and Number)


         Vancouver, British Columbia, Canada  V6E 2E9
         -----------------------------------------------------------------------
         City, State and Zip Code

--------------------------------------------------------------------------------
PART II -- RULES 12b - 25(b) and (c)
--------------------------------------------------------------------------------

If the subject report could not be filed without  unreasonable effort or expense
and the  registrant  seeks relief  pursuant to Rule 12b - 25(b),  the  following
should be completed. (Check box if appropriate.)

     [X]  (a)  The reasons  described in  reasonable  detail in Part III of this
               form could not be eliminated without unreasonable effort expense;

     [X]  (b)  The subject annual report,  semi-annual report, transition report
               on Form  10-K,  Form  20-K,  Form  11-K,  Form N-SAR or a portion
               thereof  will be filed on or before the  fifteenth  calendar  day
               following  the  prescribed  due date;  or the  subject  quarterly
               report or  transition  report  on Form 10-Q or a portion  thereof
               will be filed on or before the fifth  calendar day  following the
               prescribed due date; and


     [ ]  (c)  The accountant's  statement or other exhibit required by Rule 12b
               - 25(c) has been attached if applicable.

--------------------------------------------------------------------------------
PART III - NARRATIVE
--------------------------------------------------------------------------------

State below in reasonable  detail the reasons why Form 10-K,  11-K,  20-F, 10-Q,
N-SAR,  transition  report or a portion  thereof  could not be filed  within the
prescribed time period. (Attach extra sheets if needed.)

     Due to its international operations and recent acquisition of Oriental Wave
     Holdings,  Ltd., Dragon Pharmaceutical Inc. needs more time to complete its
     Form 10-QSB for the quarter period ended June 30, 2005.

--------------------------------------------------------------------------------
PART IV - OTHER INFORMATION
--------------------------------------------------------------------------------

(1)  Name  and  telephone  number  of  person  to  contact  in  regard  to  this
     notification.

     Garry Wong                                         (604) 669-8817
     ---------------------------------------------------------------------------
     (Name) (Area Code and Telephone Number)

(2)  Have all other periodic  reports  required under section 13 or 15(d) of the
     Securities Exchange Act of 1934 or section 30 of the Investment Company Act
     of 1940 during the preceding 12 months or for such shorter  period that the
     registrant was required to file such report(s) been filed? If the answer is
     no, identify report(s).

     [X] Yes                    [ ] No

(3)  Is it anticipated that any significant change in results of operations from
     the corresponding  period for the last fiscal year will be reflected by the
     earnings  statements  to be  included  in the  subject  report  or  portion
     thereof? Based on current information, no.

     [ ] Yes                    [X] No


                           DRAGON PHARMACEUTICAL INC.
--------------------------------------------------------------------------------
                (Name of Registrant as specified in its charter)

has  caused  this  notification  to be signed on its  behalf by the  undersigned
thereunto duly authorized.


Date:    August 16, 2005                  By:  /s/ Garry Wong
                                               ------------------------------
                                               Garry Wong, Principal
                                               Financial Officer